Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bcl-2 antisense therapy in B-cell malignancies.

Asher Chanan-Khan1

  • 1Department of Medicine, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA. asher.chanan-khan@roswellpark.org

Blood Reviews
|March 24, 2005
PubMed
Summary

Bcl-2 protein overexpression drives chemotherapy resistance in B-cell cancers. Bcl-2 antisense therapy shows promise in clinical trials for reversing resistance and improving survival in these aggressive diseases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Mayo Clinic Systematic Management and Risk-Adapted Therapy for Lymphoid Malignancies (lySMART) Consensus Guidelines 2026.

Mayo Clinic proceedings·2026
Same author

Number needed to treat to avoid progression and death and cost analysis: zanubrutinib versus acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Future oncology (London, England)·2026
Same author

Multi-omics analysis reveals a unique epigenetic signature in <i>MYD88</i> wild-type Waldenström macroglobulinemia.

Haematologica·2025
Same author

Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.

Med (New York, N.Y.)·2025
Same author

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia.

Journal of managed care & specialty pharmacy·2025
Same author

The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.

Leukemia·2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Bcl-2 protein overexpression is linked to chemotherapy resistance, aggressive disease, and poor survival in B-cell lymphoproliferative disorders.
  • This overexpression disrupts the intrinsic apoptotic pathway, protecting malignant cells from death signals like chemotherapy or radiotherapy.

Purpose of the Study:

  • To investigate the potential of downregulating Bcl-2 oncoprotein as a therapeutic strategy for clinically aggressive B-cell malignancies.
  • To evaluate the efficacy of Bcl-2 antisense therapy in reversing chemotherapy resistance and enhancing treatment outcomes.

Main Methods:

  • Preclinical studies utilizing Bcl-2 antisense to decrease oncoprotein levels in malignant lymphoid cells.
  • Ongoing clinical trials assessing oblimersen (Bcl-2 antisense) in patients with non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma.

Main Results:

  • Preclinical data demonstrate that Bcl-2 antisense can effectively reduce Bcl-2 oncoprotein levels.
  • Bcl-2 antisense reversed chemotherapy resistance and enhanced the anti-apoptotic effects of other therapeutic agents in preclinical models.
  • Early clinical trial results for oblimersen are promising, supporting the proof of principle for Bcl-2 downregulation.

Conclusions:

  • Downregulation of Bcl-2 represents a potential novel therapeutic approach for aggressive B-cell malignancies.
  • Bcl-2 antisense therapy, exemplified by oblimersen, shows promise in overcoming chemotherapy resistance and improving treatment efficacy.
  • Further clinical trials and mature data will clarify the definitive role of Bcl-2 antisense therapy in managing B-cell cancers.

Related Experiment Videos